Search | Clinical Trials Finder

Conditions: Uveal Melanoma
Interventions: Darovasertib, Primary Local Therapy; Drug · Procedure
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 35
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more

Conditions: Melanoma, Ocular
Interventions: Melphalan/HDS; Combination Product
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Tucson, Arizona • Palo Alto, California • Tampa, Florida + 7 more

Conditions: Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions: C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau; Diagnostic Test
Lead sponsor: Jennifer Whitwell; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Retinoblastoma
Interventions: Melphalan hydrochloride; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Sham; Drug · Other
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
Interventions: RO7293583, Tocilizumab, Obinutuzumab, Adalimumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: MR-C-014; Device
Lead sponsor: MedRhythms, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Progressive Supranuclear Palsy
Interventions: alpha-lipoic acid and L-acetyl carnitine; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Progressive Supranuclear Palsy, Neurological Disorders
Interventions: CoQ10; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions: QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%); Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: TBio-4101, Pembrolizumab; Biological · Drug
Lead sponsor: Turnstone Biologics, Corp.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Irvine, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions: Anti-Parkinson medication, Deep Brain Stimulation; Drug · Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Telangiectasia
Interventions: Ranibizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease Dementia, Parkinson Disease, Parkinson's Disease and Parkinsonism, Lewy Body Parkinsonism, Dementia With Lewy Bodies, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, Vascular Parkinsonism
Interventions: Parkinson Disease Standard Care, Online Community-Supported Palliative Care; Other
Lead sponsor: University of Rochester; Other
Eligibility: 40 Years and older
Enrollment: 632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Ocular Motility Disorder
Interventions: current standard of care treatments; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 17
States / cities: Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more

Conditions: Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
Interventions: Acthar Gel 80 UNT/ML Injectable Solution; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,489 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Neuromyelitis Optica
Interventions: C1-esterase inhibitor (Cinryze); Drug
Lead sponsor: Michael Levy; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury, Chronic Progressive External Ophthalmoplegia
Interventions: Magnetic Levator Prosthesis (MLP), Kinesiotape Frontalis Sling (KTFS); Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 5 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Open Angle Glaucoma, Myopia
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2030
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amblyopia, Strabismus
Interventions: Patching therapy, Glasses; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 6 Months to 90 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 7 Years to 18 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis and Saint Paul, Minnesota

Search by objective public record fields.

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Imaging Studies in Corticobasal Syndrome

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

Effects of Coenzyme Q10 in PSP and CBD

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Gait Analysis in Neurological Disease

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

Community Outreach for Palliative Engagement -- Parkinson Disease

Evaluation and Treatment of Pediatric Eye Diseases

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation

Familial Investigations of Childhood Cancer Predisposition

Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis

Diagnostic Innovations in Glaucoma Study

Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy

DKA Optic Ultrasound